Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand

• Main Authors: Bailey H., Collins I., Childs T., Tostevin A., Goetghebuer T., Valerius N., Königs C., Galli L., Marczynska M., Marques L., Ene L., Voronin E., Okhonskaia L., Noguera-Julian A., Rojo P., Amador J., Naver L., Rudin C., Jourdain G., Tookey P., Giaquinto C., Judd A.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84984677356&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42667

©2016 International Medical Press. Background: Surveillance for mid- and long-term antiretroviral therapy (ART) toxicity in children is important for informing treatment guidelines. We assessed the safety of darunavir (DRV) and atazanavir (ATV), commonly used as second-line protease inhibitors follo...